Butyrophilin 3A1-Butyrophilin 2A1 complex (BTN3A1/BTN2A1)

The phosphoantigen-presenting complex is a heteromeric molecular assembly consisting of Butyrophilin 3A1 (BTN3A1) and Butyrophilin 2A1 (BTN2A1) that is essential for the activation of Vγ9Vδ2 T cells (Rigau et al., Science 2020). It acts as a metabolic sensor that detects intracellular levels of phosphoantigens, such as isopentenyl pyrophosphate (IPP), which accumulate in cancer cells due to a dysregulated mevalonate pathway or in cells infected by certain pathogens (Vavassori et al., Nature Immunology 2013). Mechanistically, these phosphoantigens bind to the intracellular B30.2 domain of BTN3A1, inducing a conformational change that allows BTN3A1 to interact with BTN2A1. BTN2A1 then directly binds to the Vγ9 chain of the γδ T-cell receptor (TCR), facilitating a non-MHC-restricted immune response (Karunakaran et al., Immunity 2020). This unique 'inside-out' signaling mechanism makes the complex a high-value target for cancer immunotherapy, as it allows for the selective targeting of metabolically stressed cells. Therapeutic agents like the monoclonal antibody ICT01 are designed to stabilize the active state of this complex to trigger potent anti-tumor cytotoxicity by γδ T cells (ImCheck Therapeutics, 2024). Additionally, bisphosphonates like zoledronic acid are used clinically to indirectly activate this complex by increasing endogenous phosphoantigen levels. The complex is currently being investigated in clinical trials for various solid and hematological malignancies due to its ability to mobilize a broad and rapid immune response.

Other names

Phosphoantigen-presenting complexBTN3A1/BTN2A1 complexButyrophilin complexVγ9Vδ2 T cell activation complex

Agonistic monoclonal antibodies (e.g., ICT01) bind to the extracellular domain of BTN3A1 to stabilize the active conformation of the BTN3A1/BTN2A1 complex, while bisphosphonates (e.g., Zoledronic acid) inhibit farnesyl pyrophosphate synthase to cause intracellular accumulation of phosphoantigens that bind the BTN3A1 B30.2 domain; both pathways lead to the direct activation of Vγ9Vδ2 T cells.